Rice University will launch online classes next week for small business leaders planning their recovery. Courtesy of Rice University

Houston small businesses and startups have a long road of recovery ahead of them, and Rice University and some of its partners want to help local entrepreneurs prepare for it.

Rice University's Susanne M. Glasscock School of Continuing Studies has partnered with the Ion — along with the Center for Houston's Future and Rice Alliance for Technology and Entrepreneurship — to launch the Back In Business Initiative. The program will begin with three courses in the week of April 20 to 24. The three courses are:

"Glasscock's mission has always been to provide education to the residents of Houston," says Robert Bruce, dean of the Glasscock School, in a news release. "We specialize in providing responsive, practical information that will help our constituents when and how they need it most. To assist our struggling Houston small business community during this crisis, we created this trilogy of courses to help analyze their current situation, use creative problem-solving and provide meaningful communications to help them weather this situation."

More classes will be added as needed. The classes have a $25 registration fee, and anyone can enroll online.

"Today's health crisis may have changed many aspects of our daily lives, but it has not affected our commitment to providing the right tools and education to help our community succeed," says Jan Odegard, senior director of academic and industry partnerships at the Ion, in the release. "We all have a role to play in meeting the challenge of COVID-19 and we are excited to be partnering with the Glasscock School of Continuing Studies to support Houston small businesses in this time of uncertainty."

The university also touts OpenRICE as a resource for businesses. The online education platform is available to the Houston community for free. Rice also has a 20 percent discount for all professional studies courses and programs enrollment — with the ability to postpone for up to a year without a fee. This deal runs through April 30.

Rice University's Glasscock school of Continuing Studies is the Ion's first academic partnership to be announced. Courtesy of Rice University

The Ion names inaugural academics partner, course programming for Houston hub

Teaming up

A burgeoning entrepreneurship hub has taken a major step forward in its development with the announcement of its first academic partner and coursework for the partnership.

The Ion has teamed up with Rice University's Glasscock School of Continuing Studies to bring programming to the to-be hub, which is expected to open in early 2021.

"We are thrilled to extend our programming to the Ion constituents and Houston's innovation ecosystem," says Robert Bruce Jr., dean of Rice's Continuing Studies school, in a news release. "Continuing education, whether that takes the form of an advanced certificate or a single course, is an important part of the innovation lifecycle, and we are excited to provide this to Houston's entrepreneurs."

The school will offer a mix of online and hybrid courses and certificate programs for personal and professional development. Select courses are slated to begin on January 13, and sign-ups for the courses are live online.

"We know business leaders have many goals and responsibilities and we look forward to supporting them to achieve new levels of success through our responsive and proven programming," Bruce adds.

Some of the first semesters programming is expected to focus on computer and data science education, corporate financial planning, leadership courses, project management, and more, according to the release. Mary Lynn Fernau, the Glasscock School's director of executive and international programs, will manage the partnership.

"As The Ion seeks to increase access to flexible career development in tech and entrepreneurial programming, our partnership with the Glasscock School serves as a model for what professional activation at The Ion can look like at its best," says Gabriella Rowe, executive director of The Ion, in the release.

Trilogy Education and Rice University have joined forces for a new program. Photo courtesy of Rice University

Rice University teams up with workforce accelerator to create a first-of-its-kind fintech bootcamp

Back to school

As Rice University's campus continues to welcome back its students for a new year, the administration has big news about a new, innovative program to share.

Rice University's Glasscock School of Continuing Studies has partnered with New York-based workforce accelerator, Trilogy Education, to provide the first fintech boot camp on a college campus, according to a representative from the company.

"Technology skills are becoming foundational for many roles in the finance, energy and life science sectors," says David Vassar, assistant dean of professional and executive programs at the Glasscock School, in a news release. "We have partnered with Trilogy Education to bring to market a boot camp that prepares students to use their technical skills in a wide variety of fintech applications, from robo-advising to cryptocurrency. Whether you are already in finance or are looking for a way to transition into the industry, this program will prepare you to build a meaningful career in the fast-moving world of fintech."

Rice University FinTech Boot Camp is a 24-week program, and the inaugural class began in July. Enrollment for the next round is open from now until November 18. The program will provide students with core coding languages and technical tools that are crucial in the industry as well as pertinent technologies like machine learning and cryptocurrency. The participants will also have career-planning services and will receive a Certificate in Financial Technology from Rice.

The financial industry is booming in Houston, per the release, and companies are in competition for trained talent. Institutions like U.S. Bancorp and JPMorgan Chase have more coding positions open than Apple and Google, the release reveals, and according to data from Burning Glass, the country has added over 1.5 million fintech jobs in the past 8 years.

"The Rice University FinTech Boot Camp comes at a critical moment of need as the city of Houston transforms itself into a national hub for enterprise technology," says Robert Bruce, dean of the Glasscock School, in the release. "We've seen several fintech companies choose Houston to open new office locations and a rising demand from our longstanding industries like energy and manufacturing to transform themselves into technology and data-driven businesses."

Last year, the school launched its first boot camp in partnership with Trilogy. The Rice University Data Analytics Boot Camp has recently grown to expand to a new location in the Energy Corridor, the release states.

"Rice University's Glasscock School of Continuing Studies is playing an important role in building the digitally skilled workforce that Houston needs to support a growing innovation economy," says Dan Sommer, CEO and founder of Trilogy Education, in the release. "The Rice University FinTech Boot Camp will help working adults in Houston capitalize on the exploding demand for technology and data skills and spur additional investment in fintech throughout the region."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”